GlassScriptPhysician profile
Gibran Hamid Mahmud
NPI 1518132489
$20,993.97
in general payments reported to CMS, 2019-2025
71 companies · $3,656 in 2025
The $3,656 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,857 · 2020: $905 · 2021: $1,879 · 2022: $3,705 · 2023: $4,382 · 2024: $3,611 · 2025: $3,656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,290.93 |
| Education | $357.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,169.41 | 2019-2025 | |
| Janssen Biotech, INC. | $1,647.25 | 2019-2025 | Erleada, Rybrevant, Darzalex |
| Merck Sharp & Dohme LLC | $1,282.17 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $1,067.46 | 2019-2025 | |
| Daiichi Sankyo INC. | $994.98 | 2019-2025 | Enhertu, Injectafer, Datroway |
| E.R. Squibb & Sons, L.L.C. | $960.40 | 2019-2025 | Opdivo, Opdualag |
| Genentech USA, INC. | $904.57 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Genzyme Corporation | $859.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $825.04 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Abbvie INC. | $765.80 | 2019-2025 | |
| Celgene Corporation | $699.07 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Incyte Corporation | $689.34 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Gilead Sciences, INC. | $505.39 | 2019-2025 | Trodelvy |
| Lilly USA, LLC | $472.01 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Amgen INC. | $420.47 | 2019-2023 | Kyprolis, Lumakras, Blincyto |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gibran Mahmud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.